Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M141,410Revenue $M37,075Net Margin (%)12.3Altman Z-Score--
Enterprise Value $M140,146EPS $1.8Operating Margin %17.4Piotroski F-Score--
P/E(ttm)29.8Beneish M-Score--Pre-tax Margin (%)16.1Higher ROA y-yN
Price/Book2.310-y EBITDA Growth Rate %2.7Quick Ratio--Cash flow > EarningsN
Price/Sales3.75-y EBITDA Growth Rate %-2.5Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow129y-y EBITDA Growth Rate %6.0ROA % (ttm)9.1Higher Current Ratio y-yN
Dividend Yield %3.0PEG--ROE % (ttm)15.8Less Shares Outstanding y-yN
Payout Ratio %85.0Shares Outstanding M2,639ROIC % (ttm)15.6Gross Margin Increase y-yN

Gurus Latest Trades with SNY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYKen Fisher 2015-06-30 Add0.02%$48.81 - $52.35
($50.66)
$ 53.596%Add 1.44%13,246,593
SNYNWQ Managers 2015-03-31 Add0.61%$44 - $51.12
($47.81)
$ 53.5912%Add 33.50%3,927,517
SNYJames Barrow 2015-03-31 Reduce-0.04%$44 - $51.12
($47.81)
$ 53.5912%Reduce 1.88%30,225,221
SNYHOTCHKIS & WILEY 2015-03-31 Add0.02%$44 - $51.12
($47.81)
$ 53.5912%Add 0.77%11,782,180
SNYThird Avenue Management 2015-03-31 Sold Out -0.012%$44 - $51.12
($47.81)
$ 53.5912%Sold Out0
SNYDodge & Cox 2015-03-31 Reduce-0.01%$44 - $51.12
($47.81)
$ 53.5912%Reduce 0.55%43,034,073
SNYFirst Eagle Investment 2015-03-31 Sold Out -0.0038%$44 - $51.12
($47.81)
$ 53.5912%Sold Out0
SNYKen Fisher 2015-03-31 Reduce$44 - $51.12
($47.81)
$ 53.5912%Reduce 0.21%13,058,095
SNYMario Gabelli 2015-03-31 Reduce$44 - $51.12
($47.81)
$ 53.5912%Reduce 9.53%4,700
SNYCharles Brandes 2015-03-31 Add$44 - $51.12
($47.81)
$ 53.5912%Add 0.08%2,573,969
SNYHOTCHKIS & WILEY 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 53.5911%Add 18.16%11,692,693
SNYNWQ Managers 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 53.5911%Add 22.12%2,941,923
SNYCharles Brandes 2014-12-31 Add0.21%$44.4 - $55
($48.49)
$ 53.5911%Add 14.36%2,571,795
SNYJames Barrow 2014-12-31 Add0.15%$44.4 - $55
($48.49)
$ 53.5911%Add 8.87%30,804,459
SNYDavid Dreman 2014-12-31 Buy $44.4 - $55
($48.41)
$ 53.5911%New holding1,102
SNYBill Nygren 2014-09-30 Add0.27%$50.89 - $57.29
($53.73)
$ 53.59-0%Add 14.55%5,670,000
SNYFirst Eagle Investment 2014-09-30 Reduce-0.07%$50.89 - $57.29
($53.73)
$ 53.59-0%Reduce 94.39%34,157
SNYNWQ Managers 2014-06-30 Reduce-1.31%$51.23 - $54.54
($53.08)
$ 53.591%Reduce 52.34%2,602,503
SNYBill Nygren 2014-06-30 Add0.9%$51.23 - $54.54
($53.08)
$ 53.591%Add 90.38%4,950,000
SNYBill Nygren 2014-03-31 Buy 1.1%$47.77 - $53.63
($50.68)
$ 53.596%New holding2,600,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-43.59view
Sanofi10% Owner 2015-01-26Buy647,448$95-43.59view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-42.48view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-19.87view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67598.7view

Press Releases about SNY :

Quarterly/Annual Reports about SNY:

    News about SNY:

    Articles On GuruFocus.com
    Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
    Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
    Amgen’s Cholesterol Fighting Drug Receives EU Approval May 26 2015 
    Dodge & Cox Stock Fund First Quarter 2015 Commentary Apr 24 2015 
    Mt Stocks Apr 19 2015 
    Scottrade Mar 22 2015 
    Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
    Oh là là! Looking for Dividend Yield? Explore France Feb 27 2015 
    FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
    Dodge & Cox 2014 Equity Year in Review Feb 19 2015 

    More From Other Websites
    Eurozone Business Activity Seems Undeterred by Greek Crisis Jul 28 2015
    Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders? Jul 28 2015
    Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal Jul 28 2015
    Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief Jul 28 2015
    Struggling Sanofi Sends Cancer SOS to Regeneron and Another Vanity Biotech IPO Launches Jul 28 2015
    Sanofi links with Regeneron in $2.2 bln cancer drug push Jul 28 2015
    Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration Jul 28 2015
    Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration Jul 28 2015
    Sanofi Joins Regeneron in $2.2 Billion Pact for Cancer Therapies Jul 28 2015
    Sanofi paying up to $300M for rare thyroid cancer drug Jul 27 2015
    Sanofi paying up to $300M for rare thyroid cancer drug Jul 27 2015
    Why Regeneron's Approval is Bad News For Esperion Therapeutics Jul 27 2015
    New England Journal of Medicine Publishes New Analyses Confirming that Sanofi Pasteur's Vaccine... Jul 27 2015
    Have Analysts Fully Priced in Praluent to Regeneron? Jul 27 2015
    AZN sells off non-core drugs Jul 27 2015
    2:48 am Sanofi-Aventis' Genzyme acquires Caprelsa from AstraZeneca (Jul 27 2015
    Sanofi: Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy... Jul 27 2015
    Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa®... Jul 27 2015
    Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK Jul 24 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK